However, recent clinical studies have shown that Adenine nucleotide translocase-2 (ANT2) can promote tumor cells to EGFR -TKI resistance, in addition, the generation of EGFR-TKI function involves the ErbB receptor pathway, however, in cancer tissues that are resistant to EGFR-TKI, ErbB receptor-independent oncogenic pathway genes are overexpressed and the biosynthesis of partially inflammatory cytokines is too active, so it is speculated that using EGFR-TKI with antibody inhibitors may have a better chance of avoiding drug resistance (73, 74). This evidence concerns the gene EGFR and neoplasm.